

REMARKS

Pursuant to the election of group I in response to the Restriction Requirement issued on 11/19/2005, the Examiner has issued the present second restriction requirement identifying the following 2 inventions:

- I. Claims 1-5, 8-10, 19-36, drawn to catalytic antagonist of a target molecule comprising fusion proteins comprising subtilisin-type serine hydrolase conjugated to the target molecule, classified in class 435, subclass 222; and
- II. Claims 37-40, 44-47, 56-73, drawn to methods of degrading a target molecule using catalytic antagonist comprising enzyme conjugate molecule of group I, classified in class 435, 222.

III.

Pursuant to 37 C.F.R. §1.142, Applicants elect Group I, Claims 1-5, 8-10, 19-36, without traverse. Thus, Claims 1-5, 8-10, 19-36 are pending, and Claims 37-40, 44-47, 56-73 are withdrawn. In the event that the elected product claims are found allowable, Applicants reserve the right to the rejoinder of the non-elected process claims in accordance with the provisions of MPEP § 821.04.

Further, the Examiner has required that Applicants' "identify a specific enzyme conjugate comprising fusion subtilisin-type serine hydrolase conjugated to the specific target molecule" (See page 3 of the Office Action). Applicants understand that the Examiner requires the identification of a target moiety (not molecule) from the group comprising "protein, chemical compounds, antigen, lectin, nucleic acid, lipid, polypeptide, carbohydrate, dendrimer etc."

Applicants would like for the Examiner to note that the catalytic antagonist of the invention are not "fusion proteins comprising subtilisin-type serine hydrolase conjugated to the target molecule", as stated by the Examiner at page 3 of the Office Action. The catalytic antagonists of the invention are chemical chimeras comprising a subtilisin-type serine hydrolase conjugated to a target moiety. The entire conjugate is the catalytic antagonist that binds a target molecule.

Accordingly, Applicants elect "carbohydrate" as the specific target moiety.

Claims 1-5, 8-10, 20-29, and 32-36 encompass the elected invention.

The listing of claims provided herein incorporates the amendments made to the claims in response to the office action filed on June 7, 2007. The amendments to both the composition and method claims have been incorporated. Applicants have cancelled the claims previously marked withdrawn, and have identified the presently non-elected method claims as "withdrawn".

Applicants reserve the right pursuant to 37 C.F.R. §1.141 to pursue claims to the non-elected species in this application in the event that a generic claim is found allowable. Applicants also reserve the right pursuant to 35 U.S.C. §121 to file one or more divisional applications directed to the non-elected inventions or species during the pendency of the present application.

CONCLUSION

Applicants submit that this paper fully addresses the Restriction Requirement mailed November 26, 2007. Should the Examiner have any questions, the Examiner is encouraged to contact the undersigned at (650) 846-7636.

The Commissioner is authorized to charge any fees which may be required to Deposit Account No. 07-1048 (Docket No. GC571-2-C1).

Respectfully submitted,

Date: December 21, 2007

/Elena E. Quertermous/
Elena E. Quertermous
Registration No. 47,873

Danisco U.S., Genencor Division
925 Page Mill Road
Palo Alto, CA 94304
Tel: 650-846-7636
Fax: 650-845-6504